Back

Empagliflozin promotes reverse remodeling via cardiometabolic reprogramming in established pressure-overload left ventricular hypertrophy

30 August 2026 (12:15 - 13:00)
Organised by: Logo
Congress Presentation Part of: Cardiac hypertrophy and pressure overload Cardiac Hypertrophy ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Matthias Ernst

Medical University of Vienna, Vienna (Austria)

6 More presentations in this session

Presentation thumbnail
Endothelial redox signalling safeguards metabolic and transcriptional integrity and blocks middle-age cardiac hypertrophy
Ms M. Drekolia (Heidelberg, DE)
Abstract Slides
Presentation thumbnail
Ketone bodies independently of metabolic pathway attenuate cardiac hypertrophy through β-hydroxybutyrylation
Doctor J. Du (Chengdu, CN)
Abstract Slides
Presentation thumbnail
Sestrin2 protects against pressure overload–induced pathological cardiac hypertrophy via ULK1
Mr T. Liu (CN)
Abstract Slides
Presentation thumbnail
The Role of Neuropeptide Y in Human Cardiac Hypertrophy after Myocardial Infarction
Miss L. Ganzer (GB)
Abstract Slides
Presentation thumbnail
A porcine model of pressure overload–induced cardiac hypertrophy via catheter-based aortic stent implantation for aav-mediated gene therapy studies
Ms M. Corsten (Munich, DE)

Access the full session

Session thumbnail
Cardiac hypertrophy and pressure overload

The Event

Event poster

ESC Congress 2026

30 August 2026 12:15 CET
You may be interested in
thumbnail
Congress Presentation
Myocardial ketone body oxidation underlies the salutary effects of SGLT2 inhibitor treatment in heart failure
21 May 2023
thumbnail
Congress Presentation
Early reverse remodelling assessed by myocardial work after sacubitril-valsartan therapy
3 September 2019
thumbnail
Congress Session
Cardiac remodelling, fibrosis, and heart failure
31 August 2026
thumbnail
Congress Presentation
Cardiovascular protection by combination of the selective nonsteroidal MR antagonist finerenone and the SGLT2 inhibitor empagliflozin in a preclinical model of hypertension-induced end-organ damage
27 August 2021

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources